Advertisement

Breast Cancer Research and Treatment

, Volume 167, Issue 1, pp 277–288 | Cite as

Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population

  • Ying L. Liu
  • Anurag Saraf
  • Benjamin Catanese
  • Shing M. Lee
  • Yuan Zhang
  • Eileen P. Connolly
  • Kevin KalinskyEmail author
Epidemiology

Abstract

Background

Obesity may negatively affect survival in breast cancer (BC), but studies are conflicting, and associations may vary by tumor subtypes and race/ethnicity groups.

Methods

In a retrospective review, we identified 273 women with invasive BC administered Adriamycin/Taxane-based neoadjuvant chemotherapy from 2004 to 2016 with body mass index (BMI) data at diagnosis. Obesity was defined as BMI ≥30. Associations between obesity and event-free survival (EFS), using STEEP events, and overall survival (OS), using all-cause mortality, were assessed overall and stratified by tumor subtype [[Hormone Receptor Positive (HR+)/HER2−, HER2+, and Triple-Negative Breast Cancer (TNBC])] in our diverse population.

Results

Median follow-up was 32.6 months (range 5.7–137.8 months). Overall, obesity was associated with worse EFS (HR 1.71, 95% CI 1.03–2.84, p = 0.04) and a trend towards worse OS (p = 0.13). In HR+/HER2− disease (n = 135), there was an interaction between obesity and hormonal therapy with respect to OS but not EFS. In those receiving tamoxifen (n = 33), obesity was associated with worse OS (HR 9.27, 95% CI 0.96–89.3, p = 0.05). In those receiving an aromatase inhibitor (n = 89), there was no association between obesity and OS. In TNBC (n = 44), obesity was associated with worse EFS (HR 2.62, 95% CI 1.03–6.66, p = 0.04) and a trend towards worse OS (p = 0.06). In HER2+ disease (n = 94), obesity was associated with a trend towards worse EFS (HR 3.37, 95% CI 0.97–11.72, p = 0.06) but not OS. Race/ethnicity was not associated with survival in any subtype, and there were no interactions with obesity on survival.

Conclusions

Obesity may negatively impact survival, with differences among tumor subtypes.

Keywords

Breast cancer Obesity Survival Tumor subtype Race/ethnicity Neoadjuvant chemotherapy 

Abbreviations

BMI

Body mass index

NAC

Neoadjuvant chemotherapy

HR+

Hormone receptor positive

TNBC

Triple-negative breast cancer

pCR

Pathologic complete response

EFS

Event-free survival

OS

Overall survival

Notes

Funding

This study was funded by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number KL2 TR000081.

Compliance with ethical standards

Conflict of interest

Author EC has received funding from Merck and has served as a consultant for Eisai. Author KK has served as a consultant for Lilly, Biotheranostics, Amgen, Eisai, and Novartis. All other authors have no conflicts of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10549_2017_4507_MOESM1_ESM.docx (267 kb)
Supplementary material 1 (DOCX 267 kb)

References

  1. 1.
    Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384(9945):755–765CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Tsai AG, Williamson DF, Glick HA (2011) Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obesity Rev 12(1):50–61CrossRefGoogle Scholar
  3. 3.
    Gathirua-Mwangi WG, Zollinger TW, Murage MJ, Pradhan KR, Champion VL (2015) Adult BMI change and risk of breast cancer: National Health and Nutrition Examination Survey (NHANES) 2005–2010. Breast Cancer 22(6):648–656CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Jiralerspong S, Goodwin PJ (2016) Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol 34(35):4203–4216CrossRefPubMedGoogle Scholar
  5. 5.
    Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901–1914CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Niraula S, Ocana A, Ennis M, Goodwin PJ (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134(2):769–781CrossRefPubMedGoogle Scholar
  7. 7.
    Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123(3):627–635CrossRefPubMedGoogle Scholar
  8. 8.
    Allott EH, Hursting SD (2015) Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer 22(6):R365–R386CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pfeiler G, Konigsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653–2659CrossRefPubMedGoogle Scholar
  10. 10.
    Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415CrossRefPubMedGoogle Scholar
  11. 11.
    Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467–1476CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118(23):5937–5946CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA (2013) Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer 119(13):2447–2454CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hao S, Liu Y, Yu KD, Chen S, Yang WT, Shao ZM (2015) Overweight as a prognostic factor for triple-negative breast cancers in chinese women. PLoS ONE 10(6):e0129741CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Mazzarella L, Disalvatore D, Bagnardi V et al (2013) Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. Eur J Cancer 49(17):3588–3597CrossRefPubMedGoogle Scholar
  16. 16.
    Widschwendter P, Friedl TW, Schwentner L et al (2015) The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 17:129CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307(5):491–497CrossRefPubMedGoogle Scholar
  18. 18.
    Bandera EV, Maskarinec G, Romieu I, John EM (2015) Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. Adv. Nutr. 6(6):803–819CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hunt BR, Hurlbert MS (2016) Black:white disparities in breast cancer mortality in the 50 largest cities in the United States, 2005–2014. Cancer epidemiology. 45:169–173CrossRefPubMedGoogle Scholar
  20. 20.
    Tichy JR, Deal AM, Anders CK, Reeder-Hayes K, Carey LA (2015) Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150(3):667–674CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Warner ET, Ballman KV, Strand C et al (2016) Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat 159(1):109–118CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hall IJ, Newman B, Millikan RC, Moorman PG (2000) Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 151(8):754–764CrossRefPubMedGoogle Scholar
  23. 23.
    Karatas F, Erdem GU, Sahin S et al (2016) Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Breast 32:237–244CrossRefPubMedGoogle Scholar
  24. 24.
    Fontanella C, Lederer B, Gade S et al (2015) Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 150(1):127–139CrossRefPubMedGoogle Scholar
  25. 25.
    Erbes T, Stickeler E, Rucker G et al (2016) BMI and pathologic complete response to neoadjuvant chemotherapy in breast cancer: a study and meta-analysis. Clin Breast Cancer 16(4):e119–e132CrossRefPubMedGoogle Scholar
  26. 26.
    WHO (1995) Physical status: the use and interpretation of anthropometry. WHO, GenevaGoogle Scholar
  27. 27.
    Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5(5):303–311 discussion 312–303 PubMedGoogle Scholar
  28. 28.
    Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract/Am Soc Clin Oncol 6(4):195–197CrossRefGoogle Scholar
  29. 29.
    Tchrakian N, Flanagan L, Harford J, Gannon JM, Quinn CM (2015) New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers. Virchows Archiv 468:207–211CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang C, Wang S, Israel HP et al (2015) Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. SpringerPlus 4:386CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hudis CA, Barlow WE, Costantino JP et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127–2132CrossRefPubMedGoogle Scholar
  32. 32.
    Luen SJ, Salgado R, Fox S et al (2017) Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18(1):52–62CrossRefPubMedGoogle Scholar
  33. 33.
    Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Matthews SB, Thompson HJ (2016) The obesity-breast cancer conundrum: an analysis of the issues. Int J Mol Sci 17(6):989CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Renehan AG, Zwahlen M, Egger M (2015) Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15(8):484–498CrossRefPubMedGoogle Scholar
  36. 36.
    Ford NA, Lashinger LM, Allott EH, Hursting SD (2013) Mechanistic targets and phytochemical strategies for breaking the obesity-cancer link. Front Oncol 3:209CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lashinger LM, Ford NA, Hursting SD (2014) Interacting inflammatory and growth factor signals underlie the obesity-cancer link. J Nutr 144(2):109–113CrossRefPubMedGoogle Scholar
  38. 38.
    Hair BY, Troester MA, Edmiston SN et al (2015) Body mass index is associated with gene methylation in estrogen receptor-positive breast tumors. Cancer Epidemiol Biomark Prevent 24(3):580–586CrossRefGoogle Scholar
  39. 39.
    Rossi EL, de Angel RE, Bowers LW et al (2016) Obesity-associated alterations in inflammation, epigenetics, and mammary tumor growth persist in formerly obese mice. Cancer Prevent Res 9(5):339–348CrossRefGoogle Scholar
  40. 40.
    Goodwin PJ (2013) Obesity and endocrine therapy: host factors and breast cancer outcome. Breast 22(Suppl2):S44–S47CrossRefPubMedGoogle Scholar
  41. 41.
    Ewertz M, Gray KP, Regan MM et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30(32):3967–3975CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Subbaramaiah K, Howe LR, Bhardwaj P et al (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prevent Res 4(3):329–346CrossRefGoogle Scholar
  43. 43.
    Hubalek M, Oberguggenberger A, Beer B et al (2014) Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. Clin Breast Cancer 14(4):291–296CrossRefPubMedGoogle Scholar
  44. 44.
    Diorio C, Lemieux J, Provencher L, Hogue JC, Vachon E (2012) Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels. Breast Cancer Res Treat 136(2):573–579CrossRefPubMedGoogle Scholar
  45. 45.
    Sini V, Lunardi G, Cirillo M et al (2014) Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. Br J Cancer 110(5):1133–1138CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Phipps AI, Ichikawa L, Bowles EJA et al (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60–66CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    George SM, Bernstein L, Smith AW et al (2014) Central adiposity after breast cancer diagnosis is related to mortality in the health, eating, activity, and lifestyle study. Breast Cancer Res Treat 146(3):647–655CrossRefPubMedGoogle Scholar
  48. 48.
    Sun X, Nichols HB, Robinson W, Sherman ME, Olshan AF, Troester MA (2015) Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. Cancer Causes Control 26(12):1803–1811CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Liu YL, Saraf A, Catanese B et al (2017) Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population. Breast Cancer Res Treat. doi: 10.1007/s10549-017-4507-y

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Ying L. Liu
    • 1
  • Anurag Saraf
    • 2
  • Benjamin Catanese
    • 2
  • Shing M. Lee
    • 3
  • Yuan Zhang
    • 3
  • Eileen P. Connolly
    • 2
  • Kevin Kalinsky
    • 4
    Email author
  1. 1.Department of Medicine, New York Presbyterian HospitalColumbia University Medical CenterNew YorkUSA
  2. 2.Department of Radiation Oncology, New York Presbyterian HospitalColumbia University Medical CenterNew YorkUSA
  3. 3.Department of BiostatisticsColumbia University School of MedicineNew YorkUSA
  4. 4.Department of Medical Oncology, New York Presbyterian HospitalColumbia University Medical CenterNew YorkUSA

Personalised recommendations